slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 22,261-22,290
Pages 1,349
Rows per page 30
Beat
22,261-22,290 of 40,452
17
Includes a footnote regarding the reconciliation of Adjusted EBITDA.Limbach Holdings | Investor Presentation Deck | 25 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
18
Limbach Holdings | Investor Presentation Deck | 25 slidesLimbach Holdings | Investor Presentation Deck | 25 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
19
Includes year-over-year percentage change indicators for each metric.Limbach Holdings | Investor Presentation Deck | 25 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
20
The slide uses stacked bar charts to show segment contributions (GCR vs ODR) and highlights year-over-year percentage changes.Limbach Holdings | Investor Presentation Deck | 25 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
20
The chart shows a significant jump in LTM 3Q22 revenue compared to previous years.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & Proof1 hit
21
The slide features the Limoneira logo and a large number '2', indicating it is the second section of the presentation.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & Proof1 hit
22
The slide provides a financial breakdown of assets as of August 31, 2021, including a disclaimer about FMV.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
23
The slide highlights the strategic value of water rights as a tangible asset class.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
24
Limoneira | Investor Presentation Deck | 39 slidesLimoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
25
Limoneira | Investor Presentation Deck | 39 slidesLimoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
26
Slide 26 of the deck.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
27
Includes a site plan map and architectural rendering.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & Proof1 hit
28
Limoneira | Investor Presentation Deck | 39 slidesLimoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & Proof1 hit
11
The slide includes a table of financial figures and a bulleted list of liquidity/debt highlights.Lindsay Corporation | Results Presentation Deck | 17 slides · Lindsay Corporation
Conference presentation Investor relations Beat · VisualizationLoop · Logic Chain1 hit
12
The slide includes a specific footnote regarding FY21 capital expenditures related to a manufacturing operation in Turkey.Lindsay Corporation | Results Presentation Deck | 17 slides · Lindsay Corporation
Conference presentation Investor relations Beat · VisualizationLoop · Logic Chain1 hit
13
The chart is a classic cash flow bridge/waterfall.Lindsay Corporation | Results Presentation Deck | 17 slides · Lindsay Corporation
Conference presentation Investor relations Beat · VisualizationLoop · Logic Chain1 hit
29
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Team1 hit
09
Includes definitions of acronyms and citations for preclinical studies.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
10
Study methodology involves 10-week treatment on high fat/fructose/CHO diet.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
11
Study design timeline included; statistical significance noted for treatment groups.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
Includes definitions for abbreviations and source citations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
14
Company branding slide for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
16
Data from preclinical study in HF-DIO mice.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
18
Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
Includes study methodology timeline and statistical significance markers.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
22
Includes a bar chart for NASH diagnosis and a funnel diagram for Obesity patient progression.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit